KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Validating and leveraging non-SARS-CoV-2 respiratory infection as a negative control outcome in a phase 3 COVID-19 vaccine trial with extended observational follow-up.

Ethan Ashby, Holly Janes, Dean Follmann, Peter B Gilbert, Honghong Zhou, Xiaowei Wang, Bethany Girard, Frances Priddy, James G Kublin, Lawrence Corey, Kathleen M Neuzil, Lindsey R Baden, Hana M El Sahly, Bo Zhang, COVE study group

Am J Epidemiol 195(1) 168-177

PMID40838594
PMCIDPMC12448673
DOI10.1093/aje/kwaf176
发表日期2025-08-21
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 4 张 PMC Figure,均未识别为 KM 图:Figure 1::非 KM 图;Figure 2::非 KM 图;Figure 3::非 KM 图;Figure 4::非 KM 图。
摘要

摘要

Negative control outcomes (NCOs) are useful tools for hidden bias detection, but empirical evidence validating NCOs for COVID-19 is lacking. To address this gap, we examined the blinded phase of the randomized, placebo-controlled Coronavirus Vaccine Efficacy (COVE; NCT04470427) trial of the mRNA-1273 COVID-19 vaccine. We confirmed that acute respiratory illness with a positive test for a non-SARS-CoV-2 respiratory pathogen on a multiplex PCR panel was a valid NCO for COVID-19, considering that it was unaffected by vaccination (vaccine efficacy, VE = 3.3% (95% CI, -22.3 to 23.6)) yet strongly associated with COVID-19 (odds ratio = 2.95 (95% CI, 2.00, 4.24)). Subsequently, we leveraged non-SARS-CoV-2 infections to detect bias in time-varying VE estimates from COVE's blinded and booster phases. Balanced incidence of non-SARS-CoV-2 infection between vaccinated and unvaccinated COVID-19-free risk sets suggested low selection bias in VE estimates of two-dose mRNA-1273 against COVID-19 during the blinded phase (VE = 92.5% (95% CI, 88.8, 94.9) 14 days post-dose-two, stable for 5 months). In COVE's booster phase, higher non-SARS-CoV-2 incidence was observed after the single booster (intensity ratio, IR = 2.38 (95% CI, 1.75, 3.25) 14 days post-boost), suggesting that booster VE estimates may underestimate the true VE against COVID-19. Our findings demonstrate the potential of off-target infections for unraveling complex biases in COVID-19 vaccine studies. Trial registration: NCT04470427, https://clinicaltrials.gov/study/NCT04470427.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(4,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1:Number of incident SARS-CoV-2 and non-SARS-CoV-2 infections over the duration of the COVE study in the FAS. Shown in black is the smoothed COVID-19 incidence rate per 100,000 individuals in the US population derived from Center for Systems Science and Engineering (CSSE) at Johns Hopkins University and the New York Times. 43 , 44 Dotted vertical lines correspond to pandemic hallmark dates including relaxations of stay-at-home orders, mask recommendations, and when at-home COVID-19 tests were offered for free in the US. Shown beneath are relative frequencies of respiratory infections per month and composition of SARS-CoV-2 variants in the United States over time based on GISAID data. 42
非 KM Figure
Figure 2:Cumulative incidence of (Left) non-SARS-CoV-2 infection and (Right) SARS-CoV-2 test negative ARI counted 14 days post dose two in the blinded phase. Curves were estimated from the blinded phase per-protocol population. Cumulative incidence estimates adjusted for sex, racial/ethnic URM status, randomization strata, and baseline risk score. 95% pointwise confidence intervals shown.
非 KM Figure
Figure 3:Time-varying vaccine efficacy of two-dose mRNA-1273 against COVID-19 (Left) and intensity ratio (IR) of non-SARS-CoV-2 infection (Right) as a function of days since dose two. Vaccine efficacy was estimated after a blackout period spanning dose one to 14 days after dose two to better capture the full benefit of immunization. In Non-SARS-CoV-2 analysis, participants were artificially censored at COVID-19 date to ensure risk sets were identical between analyses. Time-varying VE was modelled using cubic P-spline. In both analyses, different baseline hazards/intensities were used for different combinations of sex, racial/ethnic URM status, and randomization strata. Estimates adjusted for continuous baseline COVID-19 risk score. 95% Wald CIs shown. Dots in bottom panels denote COVID-19 and non-SARS-CoV-2 infection events grouped by randomization arm.
非 KM Figure
Figure 4:Time-varying vaccine efficacy of single mRNA-1273 boost against (Left) Delta and Omicron COVID-19 and (Right) intensity ratio (IR) of non-SARS-CoV-2 infection in the booster phase of COVE. Both time-varying VE and IR were modelled using penalized cubic P-splines. A blackout period spanning 13 days post-boost was imposed for COVID-19 outcomes to better capture full effect of vaccination. The non-SARS-CoV-2 analysis conditioned on COVID-19-free risk sets by censoring non-SARS-CoV-2 event times at COVID-19 dates and instituting an identical 13-day blackout as the COVID-19 analysis. Different baseline hazards were used for different combinations of sex, racial/ethnic URM status, randomization strata, and whether follow-up was before or after the advent of at-home COVID-19 testing. Estimates adjusted for a continuous baseline COVID-19 risk score. 95% Wald CIs shown. Bottom panels illustrate COVID-19 and non-SARS-CoV-2 infection events as dots colored by outcome and variant type. Dots with negative days since vaccination correspond to infections before boosting. Dots aligned at zero correspond to infections in individuals who were never boosted.
非 KM Figure